King Luther Capital Management Corp decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 18.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,325 shares of the company’s stock after selling 14,760 shares during the quarter. King Luther Capital Management Corp owned 0.16% of Omnicell worth $5,200,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Comerica Bank raised its holdings in Omnicell by 1.2% in the fourth quarter. Comerica Bank now owns 74,551 shares of the company’s stock valued at $4,685,000 after acquiring an additional 866 shares in the last quarter. Redmond Asset Management LLC grew its position in Omnicell by 2.3% in the 1st quarter. Redmond Asset Management LLC now owns 15,971 shares of the company’s stock valued at $1,291,000 after buying an additional 355 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Omnicell by 17.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,594 shares of the company’s stock valued at $159,000 after buying an additional 376 shares during the last quarter. Segall Bryant & Hamill LLC grew its position in Omnicell by 30.4% in the 4th quarter. Segall Bryant & Hamill LLC now owns 61,898 shares of the company’s stock valued at $3,791,000 after buying an additional 14,446 shares during the last quarter. Finally, Bellevue Group AG grew its position in Omnicell by 3.2% in the 4th quarter. Bellevue Group AG now owns 108,042 shares of the company’s stock valued at $6,616,000 after buying an additional 3,392 shares during the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.
OMCL has been the topic of several research analyst reports. Dougherty & Co boosted their target price on shares of Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, March 7th. Benchmark boosted their target price on Omnicell from $82.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Zacks Investment Research raised Omnicell from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a research note on Monday, April 29th. BidaskClub raised Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, June 20th. Finally, TheStreet cut Omnicell from a “b” rating to a “c+” rating in a research note on Thursday, April 25th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Omnicell currently has a consensus rating of “Buy” and an average target price of $79.89.
Shares of OMCL stock traded down $0.20 on Friday, hitting $86.03. 331,169 shares of the stock were exchanged, compared to its average volume of 327,943. Omnicell, Inc. has a fifty-two week low of $51.75 and a fifty-two week high of $92.59. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of 56.23, a P/E/G ratio of 2.72 and a beta of 1.15. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.96 and a quick ratio of 1.47. The business has a 50-day moving average of $82.62.
Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.38. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The business had revenue of $202.50 million for the quarter, compared to analyst estimates of $199.72 million. During the same quarter in the prior year, the company posted $0.29 earnings per share. Omnicell’s revenue was up 10.9% on a year-over-year basis. As a group, equities research analysts expect that Omnicell, Inc. will post 2.06 earnings per share for the current fiscal year.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: Analyst Ratings Trading
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.